Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study.

Riesterer, Oliver; Ademaj, Adela; Puric, Emsad; Eberle, Brigitte; Beck, Marcus; Gomez, Silvia; Marder, Dietmar; Oberacker, Eva; Rogers, Susanne; Hälg, Roger A; Kern, Thomas; Schwenne, Sonja; Stein, Jürgen; Stutz, Emanuel; Timm, Olaf; Zschaeck, Sebastian; Weyland, Mathias S; Veltsista, Paraskevi D; Wyler, Stephen; Wust, Peter; ... (2022). Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study. International journal of hyperthermia, 39(1), pp. 1078-1087. Taylor & Francis 10.1080/02656736.2022.2109763

Preview

Text document.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview

BACKGROUND

Transurethral resection of bladder tumor (TUR-BT) followed by chemoradiation (CRT) is a valid treatment option for patients with muscle-invasive bladder cancer (MIBC). This study aimed to investigate the efficacy of a tetramodal approach with additional regional hyperthermia (RHT).

METHODS

Patients with stages T2-4 MIBC were recruited at two institutions. Treatment consisted of TUR-BT followed by radiotherapy at doses of 57-58.2 Gy with concurrent weekly platinum-based chemotherapy and weekly deep RHT (41-43 °C, 60 min) within two hours of radiotherapy. The primary endpoint was a complete response six weeks after the end of treatment. Further endpoints were cystectomy-free rate, progression-free survival (PFS), local recurrence-free survival (LRFS), overall survival (OS) and toxicity. Quality of life (QoL) was assessed at follow-up using the EORTC-QLQ-C30 and QLQ-BM30 questionnaires. Due to slow accrual, an interim analysis was performed after the first stage of the two-stage design.

RESULTS

Altogether 27 patients were included in the first stage, of these 21 patients with a median age of 73 years were assessable. The complete response rate of evaluable patients six weeks after therapy was 93%. The 2-year cystectomy-free rate, PFS, LRFS and OS rates were 95%, 76%, 81% and 86%, respectively. Tetramodal treatment was well tolerated with acute and late G3-4 toxicities of 10% and 13%, respectively, and a tendency to improve symptom-related quality of life (QoL) one year after therapy.

CONCLUSION

Tetramodal therapy of T2-T4 MIBC is promising with excellent local response, moderate toxicity and good QoL. This study deserves continuation into the second stage.

Interest & Impact

Downloads

64 since deposited on 24 Aug 2022
36 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item